Prescription Drugs
- Presentation
CBO’s Recent Appeals for New Research on Health-Related Topics
Presentation by Tamara Hayford, CBO’s Deputy Director of Health Analysis, to the Members’ Roundtable of No Patient Left Behind.
- Report
Answers to Questions for the Record Following a Hearing on Health Care Spending
The Subcommittee on Health of the House Committee on Energy and Commerce convened a hearing at which Chapin White, CBO’s Director of Health Analysis, testified. This document provides CBO’s answers to questions submitted for the record.
- Report
Answers to Questions for the Record Following a Hearing on The Budget and Economic Outlook: 2024 to 2034
The House Committee on the Budget convened a hearing at which Phillip L. Swagel, CBO's Director, testified. This document provides CBO’s answers to questions submitted for the record.
- Presentation
CBO’s Work on Health Care and a Call for New Research
Presentation by Chapin White, CBO’s Director of Health Analysis, at the David Rogers Health Policy Colloquium, Weill Cornell Medicine.
- Presentation
The Federal Perspective on Coverage of Medications to Treat Obesity: Considerations From the Congressional Budget Office
Presentation by Noelia Duchovny, an analyst in CBO’s Health Analysis Division, at the National Academies’ Roundtable on Obesity Solutions.
- Report
Answers to Questions for the Record Following a Hearing on the Oversight of CBO
The House Committee on the Budget convened a hearing at which Phillip L. Swagel, CBO's Director, testified about the work of CBO. This document provides CBO’s answers to questions submitted for the record.
- Report
Additional Information About Drug Price Negotiation and CBO’s Simulation Model of Drug Development
In response to a request from Budget Committee Chairman Jodey Arrington and Congressman Michael C. Burgess, CBO provides information about its analysis of federal policies that affect the development of new drugs in the United States.
- Blog Post
A Call for New Research in the Area of New Drug Development
To enhance its work for the Congress, CBO is looking for new research that examines how changes in pharmaceutical companies’ expected future profits affect the development of new drugs and health outcomes.
- Report
Answers to Questions for the Record Following a Hearing on Alternative Payment Models and the Slowdown in Federal Health Care Spending
The Senate Committee on the Budget convened a hearing at which Chapin White, CBO’s Director of Health Analysis, testified. This document provides CBO’s answers to questions submitted for the record.
- Blog Post
A Call for New Research in the Area of Obesity
To enhance its work for the Congress, CBO is looking for new research on factors that affect the use of anti-obesity medications and the impact of that use on other health care spending.